Molecular Diagnostics Market Size, Share, Growth, Global Forecast 2030

Extensive industry analysis and market share data are available in the recently released report “Molecular Diagnostics Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2030″ by Renub Research. The study looks at the competitors, geographical areas, and growth potential of the clinical molecular diagnostics market.


Molecular Diagnostics Market is anticipated to expand at a compound annual growth rate (CAGR) of 7.40% from 2023 to 2030


At the nexus of biotechnology and healthcare lies the dynamic and quickly evolving molecular diagnostics market, encompassing a spectrum of technologies and strategies for analyzing biological markers at the molecular level to diagnose and display illnesses. Fueled by advancements in genomics, a heightened understanding of diseases’ molecular bases, and a growing emphasis on personalized medication, this market is characterized by non-stop innovation and strategic collaborations between international pharmaceutical companies and local healthcare establishments. With an unwavering awareness of addressing unmet medical needs, the molecular diagnostics market is poised for sustained growth, serving as a linchpin in shaping the future panorama of healthcare.


Moreover, the molecular diagnostics market prospers on increasing expertise of disease molecular bases, coupled with technological breakthroughs that enhance diagnostic accuracy and inform therapeutic decisions. A growing emphasis on personalized remedies propels the demand for molecular diagnostics, enabling tailored cures based on individual genetic profiles. Ongoing innovation, driven by collaborations between worldwide pharmaceutical businesses and local healthcare establishments, addresses unmet medical desires and integrates cutting-edge technologies. This collaborative approach positions the market at the leading edge of imparting solutions for complex healthcare challenges. With advancing technology and deepening know-how of disease molecular bases, the molecular diagnostics market is set for sustained growth, emerging as a transformative force shaping the future of healthcare. Hence, the Global Molecular Diagnostics Market will therefore grow to a size of US$ 28.17 billion by 2030.


Likewise, in the molecular diagnostics market, PCR technology is pivotal for DNA amplification and detecting disease-associated genetic sequences. The versatile and precise PCR section holds an extensive percentage across numerous diagnostic packages. Simultaneously, diagnostics laboratories are vital for molecular testing services, gaining significance amid the growing demand for precision medication. Expected to maintain constant growth, this sector is propelled by enhanced diagnostic capabilities and the rising incidence of complex illnesses. Notably, with sturdy healthcare infrastructure and massive research investments, China emerges as a key growth contributor, exhibiting the quickest growth rate due to proactive government initiatives fostering advanced diagnostic generation adoption.


Due to its indispensable role in diagnostic testing, the reagents segment is poised to sustain its leading position in the molecular diagnostics market

As a fundamental element, reagents are crucial for various molecular diagnostic strategies, including PCR and DNA sequencing. The ongoing advancements in molecular diagnostics, coupled with a surge in demand for accurate and speedy testing strategies, ensure the continued prominence of the reagents section. Its pivotal feature in enabling precise molecular evaluation positions it to preserve a central role in the foreseeable future of molecular diagnostics.


Product Segment – The Molecular Diagnostics Market has been covered from three viewpoints.


  1. Reagents& kits
  2. Instruments
  3. Software& Services


The oncology sector anticipates a substantial growth rate in the molecular diagnostics market


Advancements in genomic and molecular studies have led to the development of targeted therapies and personalized remedy alternatives for cancer patients. This has amplified the need for unique and early cancer detection, driving the adoption of molecular diagnostics. Also, the increasing occurrence of cancer instances internationally further propels the growth of molecular diagnostics in oncology, making it a high-capability segment with a promising growth rate.


Application – The Molecular Diagnostics Market has been covered from five viewpoints


  1. Oncology
  2. Infectious Disease
  3. Genetic Testing
  4. Blood Screening
  5. Others


Due to its unparalleled role in DNA amplification, the Polymerase Chain Reaction (PCR) segment commands the highest share in the molecular diagnostics market.


Widely employed for its accuracy and sensitivity, PCR is pivotal in detecting and quantifying genetic material, facilitating disease diagnosis and monitoring. The versatility of PCR applications, ranging from infectious diseases to genetic disorders, makes it a cornerstone technology. Its robust performance, efficiency, and broad diagnostic utility contribute to the PCR segment’s dominance in holding the highest market share.


Request a free sample copy of the report:


Technology – The Global Molecular Diagnostics Market has been covered from six viewpoints


  1. Polymerase Chain Reaction
  2. Hybridization
  3. Isothermal Nucleic Amplification Technology (INAAT)
  4. Chips & Microarrays
  5. DNA Sequencing
  6. Others (Mass Spectrometry, TMA)



The diagnostics laboratories are poised to sustain their growth in the molecular diagnostics market because of their central role in precise and comprehensive testing services


As the demand for molecular diagnostics grows, laboratories play a crucial role in conducting complex tests and interpreting results accurately. The increasing prevalence of infectious diseases, genetic disorders, and cancer necessitates advanced diagnostic capabilities, further propelling the significance of Diagnostics Laboratories. This sector’s expertise in molecular testing positions it to maintain its pivotal role throughout the forecast period.


End-User – Global Molecular Diagnostics Market has been covered from three viewpoints


  1. Hospitals & Clinics
  2. Diagnostics Laboratories
  3. Others


During the forecast period, China is anticipated to exhibit the fastest growth in the molecular diagnostics market


The robust healthcare infrastructure in the United States, rising investments in research and development, and a large population contribute to increased demand for advanced diagnostics. Also, the growing awareness of personalized medicine and the prevalence of chronic diseases drive the adoption of molecular diagnostics in China. According to the World Health Organization (WHO), chronic diseases account for 88% of all deaths in China. The leading chronic diseases in China are cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes. Favorable government initiatives and an expanding middle class further accelerate market growth, positioning China as a key player in the industry.




  1. United States
  2. Canada
  3. Germany
  4. United Kingdom
  5. France
  6. Italy
  7. Spain
  8. Switzerland
  9. Japan
  10. China
  11. India
  12. Australia
  13. South Korea
  14. Indonesia
  15. Brazil
  16. Argentina
  17. Mexico
  18. South Africa
  19. Saudi Arabia
  20. United Arab Emirates
  21. Rest of World


Competitive Landscape


Prominent companies in the molecular diagnostics market include Abbott Laboratories, Myriad Genetics, Roche Diagnostics, BioMerieux SA, Danaher Corporation, Qiagen NV, Bio-rad Laboratories Inc., and Hologic (Gen-Probe).


Company Insights


  • Overview
  • Recent Development and Initiatives
  • Sales Analysis


Analysis of the companies present


  • Abbott Laboratories
  • Myriad Genetics
  • Roche Diagnostics
  • BioMerieux SA
  • Danaher Corporation
  • Qiagen NV
  • Bio-rad Laboratories Inc.
  • Hologic (Gen-Probe)


Related Reports


Teleradiology Market size is expected to reach US$ 17.38 Billion by 2030

Clinical Chemistry Analyzer Market size is expected to attain US$ 19.02 Billion by 2030

Lung Cancer Screening Market size is projected to reach US$ 4.36 Billion by 2028


About the Company:

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.


Media Contact:


Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076





Related Articles

Leave a Reply

Back to top button